Luspatercept met the primary endpoints in its first two Phase III tests – in transfusion-dependent beta-thalassemia and myelodysplastic syndromes (MDS) in the BELIEVE and MEDALIST studies, respectively – but Acceleron Pharma Inc. CEO Habib Dable pointed to key secondary endpoints in both clinical trials that could be the most important data points to treating physicians.
'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS
Acceleron/Celgene’s drug was effective across all endpoints in transfusion-dependent beta-thalassemia and myelodysplastic syndromes, but Acceleron CEO Habib Dable notes key secondary endpoints could be most meaningful to doctors treating these patients.
More from Clinical Trials
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.